Immutep Limited (ASX: IMM; NASDAQ: IMMP) (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel
immunotherapies for cancer and autoimmune disease, today announced that Marc Voigt, CEO, and Deann Miller, COO, will participate in two upcoming investor conferences.
For more information, download the attached PDF.
Download this document
